CSX Corporation vs Davita Inc — how do they compare? CSX Corporation trades at $50 (market cap $92.24B), while Davita Inc trades at $232 (market cap $15.12B). The key difference: CSX Corporation is far larger — about 6.1× Davita Inc's market cap, and CSX Corporation pays a 1.13% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| CSX | DVA | |
|---|---|---|
Market Cap | $92.24B | $15.12B |
Sector | Industrials | Health |
52-Week High | $49.92 | $235.71 |
52-Week Low | $32.05 | $103.87 |
Enterprise Value | $110.47B | $27.67B |
Dividend Yield | 1.13% | — |
Signals from Pluang's Aura AI — not financial advice
CSX trades at $49.64, up 0.47% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed recent earnings, beating in Q1 2026 but missing in Q4 2025, with Q2 2026 results expected soon. Revenue has trended down from $14.9B in 2022 to $14.1B in 2025, though net margins remain above 20%. Strong cash flow from operations supports dividends, including a recent $0.14 payout.
Outlook is cautiously optimistic given analyst consensus favoring Buy ratings (56.52%) and a price target near $48.87. Risks include declining revenue, high debt levels, and valuation multiples above industry norms. Earnings growth and operational efficiency gains are key catalysts for upside, but macroeconomic pressures on freight demand pose headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →